Edgar E. W. Braendle, MD, PhD
Dr. Braendle received his medical degree and doctorate at RWTH Aachen University in Germany and completed a postdoctoral lecturing qualification (habilitation) at the University of Ulm, also in Germany. As an associate professor at the University of Ulm, he led a research laboratory funded by the German Research Foundation and a phase-I clinical trial unit. His research work focused on translational medicine and development of new diagnostics.
Dr. Braendle is board certified in internal medicine, oncology, pharmacology, and urology, and is the recipient of seven national and international awards, including the Maximilian Nitze Award from the German Society of Urology. He co-authored two Friends for Cancer Research proposals to the FDA; in 2014, he was elected to The Journal of Precision Medicine editorial board.
Dr. Braendle has spent nearly two decades in drug and in vitro diagnostic (IVD) development at two major pharmaceutical companies. He was recently the senior VP and global head of Companion Diagnostics at Novartis, where he advanced twelve companion diagnostic programs into full development and led successful clinical efficacy trials for three novel diagnostic tests. He has developed a prognostic signature for stage I non-small cell lung cancer and a urinary protein marker panel for predicting acute renal failure following cardiac surgery.